The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Humana Inc. (HUM), headquartered in Louisville, Kentucky, provides medical and specialty insurance products. With a market cap of $46.7 billion, the company offers coordinated health care through health maintenance organizations, point-of-service plans, and administrative services products.

Shares of medicare giant have outperformed the broader market over the past year. HUM has gained 36.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.6%. In 2026, HUM stock is up 50.3%, surpassing the SPX's 13.9% rise on a YTD basis. 

Mark Cuban Says If You Win The Lottery, Don't Take The Lump Sum — And Tell People Who Ask for Money No, But 'Be Nice. No One Likes a Mean Billionaire'

JPMorgan Just Upgraded Salesforce Stock. Here's Why.

Why Wall Street Isn't Buying Super Micro's $60 Billion Backlog Quite Yet

Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!

Zooming in further, HUM's outperformance is also apparent compared to the iShares U.S. Healthcare Providers ETF (IHF). The exchange-traded fund has gained about 29.1% over the past year. Moreover, HUM's returns on a YTD basis outshine the ETF's 18.7% gains over the same time frame.

Humana beat estimates thanks to stronger operational efficiency and improvements in its Stars ratings. Cost trends remained favorable, particularly among value-based care members, while G&A savings from centralizing functions and expanding outsourcing provided additional margin support. Management also reaffirmed its 2028 margin target and outlined plans for 2027 Medicare Advantage plan exits to focus on higher-value products. In addition, the company is using proceeds from the Gentiva sale to fund the MaxHealth acquisition, and a new Illinois Medicaid contract is helping drive growth beyond its core Medicare Advantage business.

On Jul. 29, HUM shares closed down by 6% after reporting its Q2 results. Its adjusted EPS of $7.61 exceeded Wall Street expectations of $6.22. The company's adjusted revenue was $40.9 billion, topping Wall Street forecasts of $40.7 billion. HUM expects full-year adjusted EPS to be $9.

For the current fiscal year, ending in December, analysts expect HUM's EPS to decline 47% to $9.09 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.

Among the 26 analysts covering HUM stock, the consensus is a "Moderate Buy." That's based on 12 "Strong Buy" ratings, 13 "Holds," and one "Strong Sell."

This configuration is more bullish than a month ago, with nine analysts suggesting a "Strong Buy," one advising a "Moderate Buy," and two recommending a "Strong Sell." 

On Aug. 10, JPMorgan Chase & Co. (JPM) analyst Lisa Gill kept a "Neutral" rating on HUM and raised the price target to $393, implying a potential upside of 2.1% from current levels.

The mean price target of $419.61 represents a 9% premium to HUM's current price levels. The Street-high price target of $513 suggests a notable upside potential of 33.3%.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com